Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets
Status:
Completed
Trial end date:
2018-12-11
Target enrollment:
Participant gender:
Summary
It is planned to compare the efficacy and safety of rabeprazole 50 mg DDR (dual delayed
release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in
patients with Gastroesophageal Reflux Disease (GERD).